Fig. 5
From: Tyrosine kinase inhibitor-loaded biomimetic nanoparticles as a treatment for osteosarcoma
Ponatinib in vivo efficacy. Mouse tumor growth quantification (a), quantification of fluorescence intensity of regions-of-interest (ROI) by IVIS analyses (b), Kaplan–Meier survival (c) of mice treated with Pon (30 mg/ml, IP injections) and Pon NPs (1.5 mg/ml IV injections) 2 times per week, for 3 weeks. *p < 0.5 Pon vs. control, Leuko Pon vs. control, Lipo Pon vs. control. n = 10 mice for each group (Leuko in red, Lip green, Pon in black, control in grey). Histological section of mice organs after the 3 weeks of Pon, Leuko and Lipo Pon-loaded NPs treatment (d). All sections were stained with hematoxylin–eosin (black arrow = immune cell infiltration). Scale bar = 10 μm